BioMeca is renowned for its innovative use of Atomic Force Microscopy (AFM) and advanced imaging techniques to provide tailored solutions for health and well-being, supporting industries such as cosmetics and pharmaceuticals. By integrating BioMeca’s cutting-edge technologies and deep expertise, Tentamus will enhance its ability to deliver comprehensive, high-value services to clients worldwide, while maintaining a strong local presence in France.

Dr. Christian Rebhan, CEO of Tentamus Group, commented: "The acquisition of BioMeca is a significant milestone in our mission to provide best-in-class analytical and consulting services. BioMeca’s expertise in biomechanics and surface analysis perfectly complements our existing capabilities, allowing us to offer even more specialized and innovative solutions to our clients in life sciences and beyond. We are excited to welcome the BioMeca team to the Tentamus family and look forward to the synergies this partnership will create."

“Joining Tentamus Group marks an exciting new chapter for BioMeca,” said Julien Chlasta and Gaël Runel, CEO and Founder of BioMeca and R&D Director, respectively. “This partnership will allow us to scale our impact, invest in new technologies, and better serve our clients with the backing of a global leader in laboratory services.”

This acquisition aligns with Tentamus’ ongoing growth strategy, which focuses on expanding its global network of specialized laboratories and strengthening its position as a trusted partner for industries requiring advanced analytical and regulatory support.

About BioMeca

BioMeca, based in Lyon, France, is a pioneer in biomechanics and mechanobiology, providing high-resolution structural and mechanical characterization of biological samples. The company’s advanced technologies, including Atomic Force Microscopy, enable groundbreaking research and development in skin biology, cosmetics, and therapeutic assessments.